Acquired hyperexcitable peripheral nerve disorders: Clinical and laboratory features, therapeutic responses, and long‐term follow‐up

Abstract

AbstractIntroduction/AimsHyperexcitable peripheral nerve disorders (HPNDs) are rare. Although their clinical and laboratory features have been well studied, information on treatment and follow‐up is limited. The aim of this study is to explore the long‐term clinical, investigative, and therapeutic profile of patients with acquired HPNDs.MethodsThis study retrospectively analyzed patients from a single tertiary care center with HPND (January 2012 to January 2022). Patients were recruited according to published inclusion and exclusion criteria. Details of clinical features, diagnostic tests, therapeutic interventions, and follow‐up were recorded. This study included patients with follow‐up of 2 or more years.ResultsA total of 32 patients (M = 26, F = 6) were studied. The common clinical features included myokymia, neuropathic or shock‐like pain, cramps, sleep disturbances, encephalopathy, cerebellar ataxia, and seizures. A total of 81.25% of patients responded favorably to corticosteroids and membrane stabilizers. Among the nonresponders, five received intravenous immunoglobulin (IVIG), and one received plasma exchange (PLEX). Two patients required rituximab due to poor responses to the above treatments. The mean duration of response was 6 weeks (4–24 weeks) from the initiation of treatment. All patients had favorable outcomes, reaching clinical remission within 1–5 years from the initiation of treatment. Only two patients had relapses. Immunotherapy could be stopped in 78% of patients within 3 years and 100% by 5 years.DiscussionChronic immunosuppression starting with corticosteroids is required for satisfactory outcomes of HPNDs. These disorders usually run a monophasic course, and relapses are uncommon.